PL2740489T3 - Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki - Google Patents
Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustkiInfo
- Publication number
- PL2740489T3 PL2740489T3 PL12819899T PL12819899T PL2740489T3 PL 2740489 T3 PL2740489 T3 PL 2740489T3 PL 12819899 T PL12819899 T PL 12819899T PL 12819899 T PL12819899 T PL 12819899T PL 2740489 T3 PL2740489 T3 PL 2740489T3
- Authority
- PL
- Poland
- Prior art keywords
- prevention
- treatment
- pharmaceutical composition
- pancreatic cancer
- pancreatic
- Prior art date
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
- 201000002528 pancreatic cancer Diseases 0.000 title 1
- 208000008443 pancreatic carcinoma Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011171310 | 2011-08-04 | ||
| EP12819899.1A EP2740489B1 (en) | 2011-08-04 | 2012-08-03 | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2740489T3 true PL2740489T3 (pl) | 2017-06-30 |
Family
ID=47629400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12819899T PL2740489T3 (pl) | 2011-08-04 | 2012-08-03 | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9409993B2 (pl) |
| EP (1) | EP2740489B1 (pl) |
| JP (1) | JP6003650B2 (pl) |
| KR (1) | KR102041832B1 (pl) |
| CN (1) | CN103717238B (pl) |
| AU (1) | AU2012290949B2 (pl) |
| BR (1) | BR112014002619A2 (pl) |
| CA (1) | CA2844037C (pl) |
| DK (1) | DK2740489T3 (pl) |
| ES (1) | ES2609846T3 (pl) |
| HU (1) | HUE030130T2 (pl) |
| MX (1) | MX351414B (pl) |
| PL (1) | PL2740489T3 (pl) |
| PT (1) | PT2740489T (pl) |
| RU (1) | RU2630638C2 (pl) |
| WO (1) | WO2013018886A1 (pl) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101667319B1 (ko) | 2008-08-05 | 2016-10-18 | 도레이 카부시키가이샤 | 암의 치료 및 예방용 의약 조성물 |
| CN102171570B (zh) | 2008-08-05 | 2014-10-15 | 东丽株式会社 | 用于检测癌的方法 |
| WO2011096533A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| JP5923984B2 (ja) | 2010-02-04 | 2016-05-25 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CA2788718C (en) | 2010-02-04 | 2019-05-21 | Shinichi Kobayashi | Caprin-1 antibody for treating and/or preventing cancer |
| EP2532364B1 (en) | 2010-02-04 | 2016-05-04 | Toray Industries, Inc. | Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer |
| RU2567657C2 (ru) | 2010-02-04 | 2015-11-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| RU2607366C2 (ru) | 2010-02-04 | 2017-01-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| JP6094220B2 (ja) | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
| PL2740794T3 (pl) | 2011-08-04 | 2018-09-28 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów |
| JP6003650B2 (ja) | 2011-08-04 | 2016-10-05 | 東レ株式会社 | 膵臓癌の治療及び／又は予防用医薬組成物 |
| JP6065591B2 (ja) | 2011-08-04 | 2017-01-25 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| MX351682B (es) | 2011-08-04 | 2017-10-25 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| CN103717738B (zh) | 2011-08-04 | 2015-07-15 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| BR112014021099A2 (pt) | 2012-02-21 | 2020-12-01 | Toray Industries, Inc | anticorpo, composição farmacêutica, dna e método de tratamento e/ou prevenção de câncer e uso de um anticorpo |
| RU2633505C2 (ru) | 2012-02-21 | 2017-10-12 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| BR112014021102A2 (pt) | 2012-02-21 | 2021-12-28 | Toray Industries | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| HUE044611T2 (hu) | 2012-02-21 | 2019-11-28 | Toray Industries | Gyógyászati készítmény rák kezelésére |
| WO2013147169A1 (ja) * | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 肝臓癌の治療及び／又は予防用医薬組成物 |
| EP2832366B1 (en) * | 2012-03-30 | 2017-11-08 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gallbladder cancer |
| JP6244912B2 (ja) | 2012-07-19 | 2017-12-13 | 東レ株式会社 | 癌の検出方法 |
| DK2876446T3 (en) | 2012-07-19 | 2019-03-11 | Toray Industries | Method for detecting cancer |
| CA2918989C (en) * | 2013-08-09 | 2021-11-02 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| WO2015076425A1 (ja) * | 2013-11-25 | 2015-05-28 | リンク・ジェノミクス株式会社 | 新規モノクローナル抗体 |
| EP3237636B1 (en) * | 2014-12-22 | 2020-10-21 | Anapa Biotech A/S | Dual quenching assay for multiplex detection of target nucleic acids |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| MX2019004779A (es) | 2016-10-28 | 2019-08-12 | Toray Industries | Composicion farmaceutica para tratamiento y/o prevencion de cancer. |
| WO2019189780A1 (ja) | 2018-03-30 | 2019-10-03 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| US20230165957A1 (en) | 2020-03-12 | 2023-06-01 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CA3175277A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CA3175129A1 (en) | 2020-03-12 | 2021-09-19 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| KR20220152318A (ko) | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| CA3175279A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2022270524A1 (ja) | 2021-06-23 | 2022-12-29 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| AU2022296193A1 (en) | 2021-06-23 | 2024-01-18 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| KR20240042415A (ko) | 2021-07-27 | 2024-04-02 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| WO2023008459A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| KR20240041917A (ko) | 2021-07-27 | 2024-04-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| CN118119409A (zh) | 2021-09-03 | 2024-05-31 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| TW200728465A (en) | 1998-07-14 | 2007-08-01 | Corixa Corp | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| AU3316600A (en) | 1999-02-22 | 2000-09-21 | Torben F. Orntoft | Gene expression in bladder tumors |
| WO2000060077A2 (en) | 1999-04-02 | 2000-10-12 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| AU1438001A (en) | 1999-10-29 | 2001-05-14 | Human Genome Sciences, Inc. | 27 human secreted proteins |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| CZ20023567A3 (cs) | 2000-03-29 | 2003-11-12 | Corixa Corporation | Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| WO2002092001A2 (en) | 2001-05-11 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| CA2476518A1 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| US20070048301A1 (en) | 2002-11-26 | 2007-03-01 | Bodary-Winter Sarah C | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| CA2524173A1 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
| JP2007516693A (ja) | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
| US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| CA2553826A1 (en) | 2004-01-26 | 2005-12-08 | Debiovision Inc. | Neoplasm-specific polypeptides and their uses |
| US7598350B2 (en) | 2004-03-19 | 2009-10-06 | Imclone Llc | Human anti-epidermal growth factor receptor antibody |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| UA94899C2 (ru) | 2005-01-21 | 2011-06-25 | Дженентек, Инк. | Фиксированное дозирование антител к her |
| JP5006802B2 (ja) | 2005-02-18 | 2012-08-22 | チルドレンズ メディカル センター コーポレイション | 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのＣｙｒ６１ |
| MX2007011024A (es) | 2005-03-11 | 2009-11-23 | Vermillion Inc | Biomarcadores para cancer de ovario y cancer de endometrio: hepcidin. |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| CA2635616A1 (en) * | 2006-01-05 | 2007-07-19 | Carlo M. Croce | Microrna expression abnormalities in pancreatic endocrine and acinar tumors |
| US8211634B2 (en) | 2006-02-14 | 2012-07-03 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| US20100015724A1 (en) | 2006-08-17 | 2010-01-21 | Peter Hornbeck | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2008031041A2 (en) | 2006-09-07 | 2008-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| ES2605646T3 (es) | 2007-10-25 | 2017-03-15 | Toray Industries, Inc. | Método para la detección de un cáncer |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| AU2009225877B2 (en) | 2008-03-18 | 2014-11-20 | Genentech, Inc. | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| KR101667319B1 (ko) * | 2008-08-05 | 2016-10-18 | 도레이 카부시키가이샤 | 암의 치료 및 예방용 의약 조성물 |
| PL2837383T3 (pl) | 2008-08-05 | 2017-07-31 | Toray Industries, Inc. | Środek indukujący odporność |
| CN102171570B (zh) * | 2008-08-05 | 2014-10-15 | 东丽株式会社 | 用于检测癌的方法 |
| MX2012001741A (es) | 2009-08-19 | 2012-03-21 | Merck Patent Gmbh | Anticuerpos para la deteccion de complejos de integrina en material incrustado en parafina fijado con formalina (ffpe). |
| SG178925A1 (en) | 2009-09-22 | 2012-04-27 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
| RU2418587C1 (ru) * | 2010-01-21 | 2011-05-20 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") | Способ лечения злокачественных опухолей головного мозга |
| RU2607366C2 (ru) | 2010-02-04 | 2017-01-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| CA2788718C (en) | 2010-02-04 | 2019-05-21 | Shinichi Kobayashi | Caprin-1 antibody for treating and/or preventing cancer |
| JP5923984B2 (ja) | 2010-02-04 | 2016-05-25 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2011096533A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| RU2567657C2 (ru) | 2010-02-04 | 2015-11-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| EP2532364B1 (en) | 2010-02-04 | 2016-05-04 | Toray Industries, Inc. | Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer |
| KR101271964B1 (ko) | 2010-07-08 | 2013-06-07 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
| PL2598531T3 (pl) | 2010-07-26 | 2021-08-30 | Progastrine Et Cancers S.À R.L. | Sposoby i kompozycje do terapii nowotworu wątroby |
| JP6094220B2 (ja) | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
| JP6065591B2 (ja) * | 2011-08-04 | 2017-01-25 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| CN103717738B (zh) * | 2011-08-04 | 2015-07-15 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| KR101968499B1 (ko) * | 2011-08-04 | 2019-04-12 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| MX351682B (es) | 2011-08-04 | 2017-10-25 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| JP6003650B2 (ja) | 2011-08-04 | 2016-10-05 | 東レ株式会社 | 膵臓癌の治療及び／又は予防用医薬組成物 |
| PL2740794T3 (pl) * | 2011-08-04 | 2018-09-28 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów |
| BR112014021099A2 (pt) * | 2012-02-21 | 2020-12-01 | Toray Industries, Inc | anticorpo, composição farmacêutica, dna e método de tratamento e/ou prevenção de câncer e uso de um anticorpo |
| RU2633505C2 (ru) * | 2012-02-21 | 2017-10-12 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| HUE044611T2 (hu) * | 2012-02-21 | 2019-11-28 | Toray Industries | Gyógyászati készítmény rák kezelésére |
| BR112014021102A2 (pt) * | 2012-02-21 | 2021-12-28 | Toray Industries | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| EP2832366B1 (en) | 2012-03-30 | 2017-11-08 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gallbladder cancer |
| WO2013147169A1 (ja) | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 肝臓癌の治療及び／又は予防用医薬組成物 |
-
2012
- 2012-08-03 JP JP2012543820A patent/JP6003650B2/ja active Active
- 2012-08-03 PT PT128198991T patent/PT2740489T/pt unknown
- 2012-08-03 EP EP12819899.1A patent/EP2740489B1/en active Active
- 2012-08-03 CA CA2844037A patent/CA2844037C/en active Active
- 2012-08-03 KR KR1020147005897A patent/KR102041832B1/ko active IP Right Grant
- 2012-08-03 BR BR112014002619-0A patent/BR112014002619A2/pt not_active Application Discontinuation
- 2012-08-03 WO PCT/JP2012/069829 patent/WO2013018886A1/ja active Application Filing
- 2012-08-03 PL PL12819899T patent/PL2740489T3/pl unknown
- 2012-08-03 AU AU2012290949A patent/AU2012290949B2/en active Active
- 2012-08-03 DK DK12819899.1T patent/DK2740489T3/en active
- 2012-08-03 CN CN201280038490.3A patent/CN103717238B/zh active Active
- 2012-08-03 ES ES12819899.1T patent/ES2609846T3/es active Active
- 2012-08-03 MX MX2014001372A patent/MX351414B/es active IP Right Grant
- 2012-08-03 HU HUE12819899A patent/HUE030130T2/en unknown
- 2012-08-03 RU RU2014108047A patent/RU2630638C2/ru active
- 2012-08-03 US US14/236,818 patent/US9409993B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014001372A (es) | 2014-03-21 |
| KR102041832B1 (ko) | 2019-11-08 |
| EP2740489A4 (en) | 2015-03-04 |
| MX351414B (es) | 2017-10-13 |
| BR112014002619A2 (pt) | 2018-10-09 |
| AU2012290949A1 (en) | 2014-03-20 |
| CA2844037A1 (en) | 2013-02-07 |
| PT2740489T (pt) | 2017-01-10 |
| RU2630638C2 (ru) | 2017-09-11 |
| JPWO2013018886A1 (ja) | 2015-03-05 |
| JP6003650B2 (ja) | 2016-10-05 |
| AU2012290949B2 (en) | 2017-03-02 |
| HUE030130T2 (en) | 2017-04-28 |
| RU2014108047A (ru) | 2015-09-10 |
| EP2740489A1 (en) | 2014-06-11 |
| WO2013018886A1 (ja) | 2013-02-07 |
| US9409993B2 (en) | 2016-08-09 |
| ES2609846T3 (es) | 2017-04-24 |
| KR20140064835A (ko) | 2014-05-28 |
| US20140308283A1 (en) | 2014-10-16 |
| CN103717238B (zh) | 2016-10-12 |
| CN103717238A (zh) | 2014-04-09 |
| CA2844037C (en) | 2020-07-14 |
| DK2740489T3 (en) | 2017-01-16 |
| EP2740489B1 (en) | 2016-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2740489T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki | |
| EP2818482A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| EP2818481A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| EP2824114A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| PL2532365T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| EP2532743A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| EP2832365A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF LIVER CANCER | |
| EP2740793A4 (en) | MEDICINAL PREPARATION FOR CANCER TREATMENT AND / OR PREVENTION | |
| EP2740796A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| PT2740794T (pt) | Composição farmacêutica para o tratamento e/ou profilaxia de cancro | |
| HUE036425T2 (hu) | Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére | |
| EP2740795A4 (en) | MEDICAMENT COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER | |
| EP2740798A4 (en) | DRUG COMPOSITION FOR CANCER TREATMENT AND / OR PREBUILDING | |
| PT2532367T (pt) | Agente farmacêutico para o tratamento e/ou prevenção do cancro | |
| PL2532366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| EP2532364A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER | |
| PL3031826T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| HK1201730A1 (en) | Treatment agent and or prophylactic agent for side effects of cancer drugs | |
| EP2962693A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF CANCER | |
| EP2687231A4 (en) | COMPOSITION FOR THE TREATMENT AND DIAGNOSIS OF PANCREATIC CANCER | |
| IL221238A0 (en) | Pharmaceutical compositions and methods for the treatment and prevention of cancer |